An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance Pharmacokinetics Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Hitanercept (Primary) ; Etanercept
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- 15 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 15 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated